Search - tctmd.com

Displaying 21 - 40 of 206

Sort: Relevancy | Date

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Daily News

How Mediterranean Diets Might Cut Mortality in Women: New Insights

Yael L. Maxwell

June 05, 2024

News Daily News

Atherosclerosis Progression May Share Traits With Tumor Growth

Caitlin E. Cox

May 08, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Todd Neale

November 22, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

Advertisement

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

How Mediterranean Diets Might Cut Mortality in Women: New Insights

Atherosclerosis Progression May Share Traits With Tumor Growth

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Less Is More: Lp(a) Much More Atherogenic Than LDL

Top General Cardiology and CVD Prevention News of 2023

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People

Mortality Risk Varies Among Patients With Very High LDL Levels

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content